NRG-GY027

Closed to Accrual & Treatment

Return to Protocol Table

Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin with Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

Principal Investigator

Katherine Fuh

Status

Closed to Accrual & Treatment

Open to Accrual

June 27, 2022

Temporarily Closed to Accrual

May 31, 2023

Open to Accrual

September 18, 2023

Closed to Accrual & Treatment

December 20, 2024


Disease Site

Gynecologic [GY] Ovarian

Phase

I

Developmental Therapeutics

No

Primary Objective

To estimate the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of ipatasertib in combination with paclitaxel and carboplatin as neoadjuvant chemotherapy for ovarian cancer. Primary objectives also include determining the feasibility of the treatment regimen once the MTD is estimated.

Patient Population

Patients with pathologically proven diagnosis of ovarian cancer: high grade serous and endometroid adenocarcinoma, grade 3 are eligible. 

Target Accrual

21

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.